ImmuCell Corporation Common Stock (ICCC)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking for a business I can understand, bought at a price that leaves room for error. ImmuCell is a small animal-health company, 73 employees, selling products such as First Defense for calf scours and Tri-Shield First Defense for dairy and beef cattle. The niche is real, but the record is mixed. In fiscal 2023, the company reported revenue of $17.5 million and a net loss of $5.8 million, or $0.75 per diluted share. In fiscal 2024, revenue rose to $26.5 million, but the net loss was $2.2 million, or $0.26 per share. In fiscal 2025, revenue reached $27.6 million, yet it still lost $1.0 million, or $0.12 per share. Recent quarters are better: in fiscal Q1 2026, revenue was $10.4 million and net income $1.9 million, or $0.21 per diluted share; in fiscal Q2 2026, revenue was $7.2 million and net income $1.8 million, or $0.20 per diluted share. FairStock reports revenue growth of 11.50%, ROE of 2.57%, ROCE of 6.25%, debt-to-equity of 0.40, and trailing free cash flow of $4.2 million. The balance sheet appears tolerable, but returns are low. Valuation is the problem. At the 2026-10-13 close of $10.79, FairStock calculates a P/E of 154.14, P/B of 3.12, EV/EBITDA of 27.95, and a Graham Number of $2.33, implying a negative margin of safety of 363.09%. A PEG of 0.58 and a FairStock Score of 32/100 do not give me comfort. This may be a turnaround, but I need durable annual profits before I can call it a value.

In plain English: ImmuCell is a small animal-health company that makes products for dairy and beef cattle, including a calf scours preventive called First Defense. The business has had recent profitable quarters but lost money in its latest full fiscal years, and its shares have moved in a wide range. Based on the supplied numbers, the stock price looks expensive compared with current earnings and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer